- Frontage Laboratories has opened a new 46,300-square-foot GMP facility in Exton, Pennsylvania, to enhance its CRDMO services.
- The site includes nine GMP suites and expands capabilities for formulation development, manufacturing, and analytical testing.
Frontage Laboratories, Inc. has officially launched its newest Contract Research, Development and Manufacturing Organization (CRDMO) facility in Exton, Pennsylvania. The grand opening took place on 22 May 2025 and marked the operational start of the 46,300-square-foot Good Manufacturing Practice (GMP) facility located at 240 Sierra Drive.
The facility features nine GMP suites—two high-potent, two aseptic, and five non-sterile—designed to support a wide range of dosage forms, including injectables, tablets, capsules, creams, gels, ointments, as well as ophthalmic and nasal products. In addition, the building houses two formulation development labs and three analytical labs, including a microbiology lab, offering integrated services to pharmaceutical and biotech clients.
This expansion strengthens Frontage Laboratories’ position in the CDMO and contract manufacturing sector, providing end-to-end support from formulation development to distribution. The company stated the new site complements its broader offerings in drug substance synthesis, DMPK, safety and toxicology, bioanalysis, and clinical trial services.
“We are grateful to all who joined us to share in our joyous occasion. The grand opening of this new CRDMO marks a significant milestone for us in the CDMO and clinical trial material supply space,” said Dr. Song Li, Founder and Executive Chairman of Frontage.
Dr. Wentao Zhang, Co-CEO, noted that the new site allows the company to be closer to clients and better respond to their development and supply requirements.
Stay ahead of trends and best practices
